

Abdominal Radiology

Pretreatment MRI Parameters as Predictive Biomarkers for Hormonal Therapy Response in Adenomyosis: A Comprehensive Analysis

Kazuhiko Morikawa, Akira Baba, Shun Kusada, Satoshi Matsushima, Yohei Ohki, Megumi Shiraishi, Yoshitake Miyamoto, Aya Igarashi, Yumari Kusano, Ayako Kawabata, Hiroya Ojiri

Department of Radiology, The Jikei University School of Medicine, Tokyo, Japan

Corresponding author: k.morikawa@jikei.ac.jp

Supplementary table 1. Demographic, clinical, and radiological characteristics of the study population.

	GnRH (n=32)	DNG (n=46)	P value
Age (years) [range]	46.0 [31–54]	43 [22-52]	0.0018
Age at menarche (years) [range]	12 [9-14] (n=20)	13 [9-16] (n=32)	0.129
Menstrual cycle length (days) [range]	28 [25-49] (n=21)	28 [25-30] (n=30)	0.819
Duration of menstruation (days) [range]	6 [3-10] (n=21)	6 [4-10] (n=31)	0.812
Infertility	5 (5/32, 15.6%)	11 (11/46, 23.9%)	0.41
History of gynecologic surgery or disease	7 (7/32, 21.9%)	14 (14/46, 30.4%)	0.671
History of hormonal therapy	7 (7/32, 21.9%)	2 (2/46, 4.3%)	0.028
≥1-month drug-free interval before MRI	2 (2/7, 28.6%) (n=7)	1 (1/2, 50%) (n=2)	1
Modified Andersch–Milsom scale			

Pre-treatment [Pts count of each grade 0/1/2/3]	2 [3/10/15/4]	2 [1/8/30/7]	0.186
Post-treatment [Pts count of grade 0/1/2/3]	1 [15/17/0/0]	1 [11/24/9/2]	0.00616
Menorrhagia			
Pre-treatment	27 (27/32, 84.4%)	28 (28/46, 60.9%)	0.0421
Post-treatment	2 (2/32, 6.3%)	10 (10/46, 21.7%)	0.108
Serum hemoglobin (g/dL)			
Pre-treatment [range]	11.2 [5.2-14.0] (n=31)	11.9 [6.4-14.1] (n=36)	0.0682
Post-treatment [range]	13.0 [8.6-14.5] (n=30)	12.7 [6.8-14.5] (n=36)	0.197
Serum CA125 (U/mL)			
Pre-treatment [range]	100.5 [16-444] (n=18)	62.5 [11-1083] (n=31)	0.198
Post-treatment [range]	57.5 [14-126] (n=10)	51 [13-149] (n=15)	0.657
Adverse effects except irregular bleeding	9 (9/32, 28.1%)	3 (3/46, 6.5%)	0.022
Irregular bleeding during treatment [Pts count of mild/severe bleeding]	9 (9/32, 28.1%) [7/2]	36 (36/46, 78.3%) [31/5]	<0.001
Unpredictable bleeding during treatment	1(1/32, 3.1%)	3 (3/46, 6.5%)	0.64
Treatment period (days) [range]	140.5 [56-407]	189 [22-686]	0.0561
Initial hormonal therapy result			<0.001
success	31(31/32, 96.9%)	28 (28/46, 60.9%)	
failure	1(1/32, 3.1%)	18 (18/46, 39.1%)	
Location 1 subtype			0.0874

Intrinsic	3 (3/32, 9.4%)	7 (7/46, 15.2%)	
Extrinsic	9 (9/32, 28.1%)	22 (22/46, 47.8%)	
Intramural	0	1 (1/46, 2.2%)	
Penetrating	20 (20/32, 62.5%)	16 (16/46, 34.8%)	
Location 2 distribution pattern			0.646
Diffuse	20 (20/32, 62.5%)	26 (26/46, 56.5%)	
Focal	12 (12/32, 37.5%)	20 (20/46, 43.5%)	
Location 3 main distribution			0.594
Anterior	6 (6/32, 18.8%)	7 (7/46, 15.2%)	
Posterior	19 (19/32, 59.4%)	30 (30/46, 65.2%)	
Lateral	1 (1/32, 3.1%)	1 (1/46, 2.2%)	
Fundus	2 (2/32, 6.3%)	6 (6/46, 13.0%)	
unclassifiable	4 (4/32, 12.5%)	2 (2/46, 4.3%)	
Ovarian endometriosis	18 (18/32, 56.3%)	34 (34/46, 73.9%)	0.143
Deep endometriosis	21 (21/32, 65.6%)	28 (28/46, 60.9%)	0.812
Uterine myoma	26 (26/32, 81.3%)	21 (21/46, 45.7%)	0.0021
Subendometrial myoma >2cm	8 (8/32, 25.0%)	2 (2/46, 4.3%)	0.15
Intramural myoma \geq 4 cm	10 (10/32, 31.3%)	2 (2/46, 4.3%)	0.0465
Shrinking in endometriotic cyst after treatment [enlarged/unchanged/reduced]	[0/3/14] (n=17)	[4/8/21] (n=21)	0.302

Shrinking in leiomyoma size after treatment [enlarged/unchanged/reduced]	[0/5/14] (n=18)	[2/17/4] (n=14)	<0.001
---	-----------------	-----------------	--------

Data are presented as number (percentage) or median [range], as appropriate. Continuous variables were compared using the Mann–Whitney U test, and categorical variables were analyzed using the chi-squared test or Fisher's exact test. Treatment failure includes discontinuation or modification due to adverse effects. DNG, dienogest; GnRH, gonadotropin-releasing hormone.